by Paul | 4th December 2023 | News
Top-line Efficacy and Safety Data on Track for Release in December 2023 London and New York, NY, December 4, 2023. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory... by Paul | 31st October 2023 | News
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extinguishment of $4.20M of payables by... by Paul | 5th October 2023 | News
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial. The dropout rate is 5.4% and unrelated to side... by Paul | 14th September 2023 | News
LONDON and NEW YORK, September 14, 2023 — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this... by Paul | 13th September 2023 | News
London and New York, NY – September 13, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced that it intends to offer to...